Recent News

November 7, 2019 at 4:05 PM EST

Summary Toggle Proteostasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

BOSTON , Nov. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
November 6, 2019 at 7:00 AM EST

Summary Toggle Proteostasis Therapeutics Announces Completion of Enrollment in Global Phase 2 Study in Cystic Fibrosis

Company Now Expects Phase 2 Top-line Data Later in Q4 of 2019 Instead of Q1 2020 Due to Rapid Enrollment BOSTON , Nov. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking
October 24, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Announces Presentations Highlighting its CFTR Modulators at the North American Cystic Fibrosis Conference

BOSTON , Oct. 24, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
October 21, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Host Cystic Fibrosis Summit on Disparity in Access to CFTR Modulators Based on Geography Featuring Members of the Cystic Fibrosis Community and Thought Leaders

BOSTON , Oct. 21, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
September 26, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

BOSTON , Sept. 26, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing,
September 19, 2019 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Announces Presentation at the UK Cystic Fibrosis Conference

BOSTON , Sept.19, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
August 7, 2019 at 4:05 PM EDT

Summary Toggle Proteostasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

BOSTON , Aug. 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today
July 25, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Initiates Dosing in Global Phase 2 Study in Cystic Fibrosis

BOSTON , July 25, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that the first patient has been dosed in the
July 23, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Announces Management Changes and Appointments

Geoffrey S. Gilmartin, MD, MMSc, to Succeed Po-Shun Lee, MD as Chief Medical Officer; Dr. Lee to Remain a Consultant for the Company Andrey E. Belous, MD, PhD, Appointed as Senior Medical Director, Joining From Galapagos NV BOSTON , July 23, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc.
June 4, 2019 at 7:00 AM EDT

Summary Toggle Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis

BOSTON , June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today